The European Commission has ordered 30,000 treatment doses of the antiviral medication remdesivir from US drugs giant Gilead, it announced Wednesday.

Sold under the brand name Veklury, remdesivir is the first medicine to be approved by the EU to treat victims of the COVID-19 pandemic in EU member states and Britain.

It is hoped the drug will shorten recovery times for patients with severe infections and it will be made available early next month. 

The first batch of doses will cost 63 million euros ($73 million) and ought to cover needs for the next few months before a second procurement contract in October.

 

                

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.